RYTM
Rhythm Pharmaceuticals, Inc.112.45
-0.07-0.06%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
7.50BP/E (TTM)
-Basic EPS (TTM)
-3.10Dividend Yield
0%Recent Filings
8-K
8-K
10-Q
8-K
Q2 revenue surges to $48.5M
Rhythm Pharmaceuticals reported Q2 2025 net product revenue of $48.5 million from IMCIVREE sales, up 67% year-over-year, fueled by Bardet-Biedl syndrome treatments while U.S. revenue hit $32.0 million. Bivamelagon's Phase 2 trial delivered significant BMI reductions of 7.7% to 9.3% in hypothalamic obesity patients; setmelanotide's Phase 3 showed -19.8% placebo-adjusted BMI drop. Cash stood at $291.0 million, bolstered by $189.2 million from a July stock offering. Regulatory filings for setmelanotide in acquired hypothalamic obesity target Q3 2025 completion.
10-Q
Q2 FY2025 results
Rhythm Pharmaceuticals posted solid Q2 FY2025 results, with product revenue hitting $48.5 million, up 67% year-over-year and 29% quarter-over-quarter from $29.1 million and $37.3 million (derived), driven by stronger U.S. sales of $32.0 million (66% of total) and international growth to $16.5 million amid expanding market access for IMCIVREE in rare obesity indications. Gross margin held steady at 88.6%, while operating loss widened to $45.3 million from $40.5 million year-over-year due to higher R&D ($42.3 million, up 40%) and SG&A ($45.9 million, up 26%) tied to clinical trials and commercialization. Diluted EPS came in at -$0.75 on 63.7 million shares, reflecting the net loss of $46.6 million versus -$0.55 last year. Cash and equivalents stood at $135.6 million, bolstered by $32.1 million from ATM equity sales, with $109.8 million in deferred royalty obligations at 17.0% effective rate; free cash flow was not disclosed in the 10-Q. The January 2024 LG Chem deal closed for $92.4 million (cash and stock), recognizing no goodwill but expensing IPR&D. Competition from emerging MC4R therapies could pressure market share.
ACAD
ACADIA Pharmaceuticals Inc.
26.80-0.46
BLRX
BioLineRx Ltd.
3.01-0.17
BMRN
BioMarin Pharmaceutical Inc.
51.77-0.35
JAZZ
Jazz Pharmaceuticals plc
169.73+0.20
LXRX
Lexicon Pharmaceuticals, Inc.
1.20-0.03
RCKT
Rocket Pharmaceuticals, Inc.
3.43+0.02
RIGL
Rigel Pharmaceuticals, Inc.
42.02-0.46
RPRX
Royalty Pharma plc
38.38-0.15
RVPH
Reviva Pharmaceuticals Holdings
0.64+0.01
ZVRA
Zevra Therapeutics, Inc.
8.12-0.05